Total cell-free DNA, carcinoembryonic antigen, and C-reactive protein for assessment of prognosis in patients with metastatic colorectal cancer

Bibliographic Details
Title:	Total cell-free DNA, carcinoembryonic antigen, and C-reactive protein for assessment of prognosis in patients with metastatic colorectal cancer
Authors:	Karen-Lise Garm Spindler, Christina Demuth, Boe Sandahl Sorensen, Julia S Johansen, Dorte Nielsen, Niels Pallisgaard, Estrid Hoegdall, Per Pfeiffer, Benny Vittrup Jensen
Source:	Tumor Biology, Vol 40 (2018)
Publisher Information:	IOS Press, 2018.
Publication Year:	2018
Collection:	LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Subject Terms:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
More Details:	In late-stage metastatic colorectal cancer, difficult treatment decisions should incorporate a thorough evaluation of the patient’s general condition and subject for shared decision making. Assessment of the individual patients’ prognosis is valuable in this setting. The aim was to analyze the prognostic value of plasma levels of total cell-free DNA, carcinoembryonic antigen and C-reactive protein in 97 heavily pretreated patients with metastatic colorectal cancer. Patients received irinotecan, cetuximab, and everolimus in a phase-2 clinical trial ( clinicaltrials.gov NCT01387880). Plasma samples were used for DNA purification and quantification of total cell-free DNA by droplet digital polymerase chain reaction. Serum carcinoembryonic antigen and C-reactive protein were analyzed by routine methods. Clinical endpoints were overall survival and progression-free survival. A total of 82 patients had blood samples available for quantification of total cell-free DNA. Patients with pre-treatment cell-free DNA levels higher than the median total cell-free DNA (9800 alleles per milliliter plasma) had a significantly shorter overall survival of 4.3 months (95% confidence interval: 3.6–5.8) compared to patients with cell-free DNA levels below the median with an overall survival of 11.3 months (95% confidence interval: 8.0–14.8, p
Document Type:	article
File Description:	electronic resource
Language:	English
ISSN:	1423-0380 10104283
Relation:	https://doaj.org/toc/1423-0380
DOI:	10.1177/1010428318811207
Access URL:	https://doaj.org/article/b7070a77eb644206b2d869fa3093c793
Accession Number:	edsdoj.b7070a77eb644206b2d869fa3093c793
Database:	Directory of Open Access Journals

More Details
ISSN:	14230380 10104283
DOI:	10.1177/1010428318811207
Published in:	Tumor Biology
Language:	English